Search research articles
Contact Us
Filters
Showing results (1-10 of 64) with videos related to
Page
of 7
Sort By:
La Revue De Medecine Interne
|
February 19, 2011
[The DNA, the thread of destiny]
M-A Loriot
La Revue De Medecine Interne
|
October 31, 2006
[Vitamin K epoxide reductase: Fresh blood for oral anticoagulant therapies]
M-A Loriot, P Beaune
Annales De Biologie Clinique
|
September 10, 2004
[Pharmacogenetics or the promise of a personalized medicine: variability in drug metabolism and transport]
D Allorge, M-A Loriot
Pathologie-Biologie
|
February 15, 2005
[Pharmacogenetics of anticancer drugs]
L de Chaisemartin, M-A Loriot
La Revue De Medecine Interne
|
April 6, 2010
[The pharmacogenetics of vitamin K antagonists: still a matter for discussion]
C Moreau, V Siguret, M-A Loriot
European Journal of Cancer (Oxford, England : 1990)
|
August 2, 2025
Letter Re: Dose-individualisation of fluoropyrimidines based on pre-treatment serum uracil levels
V Boige, C Narjoz, G Le Teuff, et al.
Clinical Pharmacology and Therapeutics
|
October 25, 2007
Acetaminophen reinforces descending inhibitory pain pathways
G Pickering, V Estève, M-A Loriot, et al.
Journal of Thrombosis and Haemostasis : JTH
|
December 18, 2012
Genetic resistance to warfarin therapy masked by amiodarone in a 2-year-old girl with mitral valve replacement
C Moreau, F Bajolle, V Siguret, et al.
Alimentary Pharmacology & Therapeutics
|
November 5, 2011
Review article: the benefits of pharmacogenetics for improving thiopurine therapy in inflammatory bowel disease
L Chouchana, C Narjoz, P Beaune, et al.
Journal of Thrombosis and Haemostasis : JTH
|
June 6, 2008
Multiple genetic alterations in vitamin K epoxide reductase complex subunit 1 gene (VKORC1) can explain the high dose requirement during oral anticoagulation in humans
L Bodin, J Perdu, M Diry, et al.
Page
of 7
Search research articles
Search
Showing results (1-10 of 64) with videos related to
Sort By:
Page
of 7
La Revue De Medecine Interne
|
February 19, 2011
[The DNA, the thread of destiny]
M-A Loriot
La Revue De Medecine Interne
|
October 31, 2006
[Vitamin K epoxide reductase: Fresh blood for oral anticoagulant therapies]
M-A Loriot, P Beaune
Annales De Biologie Clinique
|
September 10, 2004
[Pharmacogenetics or the promise of a personalized medicine: variability in drug metabolism and transport]
D Allorge, M-A Loriot
Pathologie-Biologie
|
February 15, 2005
[Pharmacogenetics of anticancer drugs]
L de Chaisemartin, M-A Loriot
La Revue De Medecine Interne
|
April 6, 2010
[The pharmacogenetics of vitamin K antagonists: still a matter for discussion]
C Moreau, V Siguret, M-A Loriot
European Journal of Cancer (Oxford, England : 1990)
|
August 2, 2025
Letter Re: Dose-individualisation of fluoropyrimidines based on pre-treatment serum uracil levels
V Boige, C Narjoz, G Le Teuff, et al.
Clinical Pharmacology and Therapeutics
|
October 25, 2007
Acetaminophen reinforces descending inhibitory pain pathways
G Pickering, V Estève, M-A Loriot, et al.
Journal of Thrombosis and Haemostasis : JTH
|
December 18, 2012
Genetic resistance to warfarin therapy masked by amiodarone in a 2-year-old girl with mitral valve replacement
C Moreau, F Bajolle, V Siguret, et al.
Alimentary Pharmacology & Therapeutics
|
November 5, 2011
Review article: the benefits of pharmacogenetics for improving thiopurine therapy in inflammatory bowel disease
L Chouchana, C Narjoz, P Beaune, et al.
Journal of Thrombosis and Haemostasis : JTH
|
June 6, 2008
Multiple genetic alterations in vitamin K epoxide reductase complex subunit 1 gene (VKORC1) can explain the high dose requirement during oral anticoagulation in humans
L Bodin, J Perdu, M Diry, et al.
Page
of 7